Tyrosinaemia treatment now available as oral suspension

Prescribers have a new liquid formulation of nitisinone as an option for the treatment of children and adults with hereditary tyrosinaemia type 1.

Orfadin 4mg/ml suspension should be shaken vigorously immediately before a dose is withdrawn and administered. The liquid is administered via an oral syringe, three of which are included in each pack. Prescribers should advise patients how to administer the correct dose. 

Further information
View Orfadin Suspension drug record
Summary of Product Characteristics
Manufacturer: Sobi

As a result of increased tyrosine levels due to nitisinone's mode of action, patients may experience eye-related adverse effects such as conjunctivitis, corneal opacity, keratitis and photophobia.

Patients taking Orfadin should be on a tyrosine- and phenylalanine- restricted diet.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Added: fludroxycortide, levofloxacin, Noriday, Ongentys...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests